

## North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 5<sup>th</sup> June 2024

### Classification of products:

**G** **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug.

#### ASR

**Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.

#### ASI

**Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

#### ASC

**Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.

#### R

**Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.

**BLACK Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.

**GREY Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meeting</b>				
None				
<b>2) New Requests</b>				
Cytisine (cystinicline) 1.5mg Tablets			✓	Requested for smoking cessation and reduction of nicotine craving in those who are willing to stop smoking.  <b>Decision:</b> deferred to confirm commissioning arrangements in City of York plus provide more information on safety profile..
<b>3) New formulations &amp; extensions to use</b>				
None				
<b>5) Products considered by NICE</b>				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA963: Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA966: Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)</b>				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
<b>TA968: Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</b>				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
<b>TA969: Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)</b>				The formulary will reflect the TAG – ICB is the responsible commissioner. Received for information
<b>TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19</b>	✓ <b>R</b>			The formulary will reflect the TAG – ICB is the responsible commissioner.
<b>6) Appeals against earlier decisions by the APC</b>				
None				
<b>7) Miscellaneous formulary decisions by the APC</b>				
None				

The following documents/guidelines were presented to and approved at the June 2024 meeting of the APC:

- HDFT Vitamin B12 Guidelines
- NY&Y APC Dapagliflozin & Empagliflozin - Prescribing information for patients with heart failure
- NY&Y Opioid substitution treatment pathway: for patients no longer able to take oral maintenance methadone in last days/weeks of life

#### DECISION SUMMARY

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the June 2024 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the June 2024 meeting of the APC:

- Nil

The following documents/guidelines were presented to the June 2024 meeting of the APC for comment:

- NY&Y Crohn's & Ulcerative colitis pathway (updated)
- HNY updated shared care guideline for valproate medicines for patients of child-bearing potential